| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.SEMARTHRIT.2004.06.003 |
| P8608 | Fatcat ID | release_iaqqzfg6afdcvhtc4zqioqunge |
| P698 | PubMed publication ID | 15609263 |
| P50 | author | Hedi Orbach | Q73740512 |
| Yehuda Shoenfeld | Q1515807 | ||
| P2093 | author name string | Moshe Tishler | |
| P433 | issue | 3 | |
| P1104 | number of pages | 9 | |
| P304 | page(s) | 593-601 | |
| P577 | publication date | 2004-12-01 | |
| P1433 | published in | Seminars in Arthritis and Rheumatism | Q15761553 |
| P1476 | title | Intravenous immunoglobulin and the kidney--a two-edged sword | |
| P478 | volume | 34 |
| Q38167486 | Adult haemophagocytic syndrome |
| Q55465940 | Adverse Effects of Immunoglobulin Therapy. |
| Q26751532 | An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome) |
| Q33670568 | Antibody status in children with steroid-sensitive nephrotic syndrome |
| Q57482179 | Assessment of renal function in patients with myositis and treated with subcutaneous immunoglobulin: a series of 24 cases |
| Q34655597 | Biologic therapy for autoimmune diseases: an update |
| Q34617420 | Case report: acute renal failure after administering intravenous immunoglobulin |
| Q36623061 | Current pharmacotherapy for the treatment of crescentic glomerulonephritis |
| Q34560483 | Drug-associated renal dysfunction and injury |
| Q36634248 | Emerging drug therapies for systemic lupus erythematosus |
| Q33385332 | Evidence for the use of intravenous immunoglobulins--a review of the literature |
| Q33778831 | Glycosylation inhibitors efficiently inhibit P-selectin-mediated cell adhesion to endothelial cells |
| Q33786811 | HLA Class Ia and Ib Polyreactive Anti-HLA-E IgG2a Monoclonal Antibodies (TFL-006 and TFL-007) Suppress Anti-HLA IgG Production by CD19+ B Cells and Proliferation of CD4+ T Cells While Upregulating Tregs |
| Q36843406 | High-dosage intravenous immunoglobulin-associated macrovacuoles are associated with chronic tubulointerstitial lesion worsening in renal transplant recipients |
| Q37543422 | Idiopathic membranous nephropathy: management strategies |
| Q30498050 | Inhibition of cell adhesion by anti–P-selectin aptamer: a new potential therapeutic agent for sickle cell disease |
| Q37532010 | Intravenous immunoglobulin in lupus panniculitis |
| Q38184615 | Intravenous immunoglobulin in systemic capillary leak syndrome: a case report and review of literature. |
| Q36302368 | Intravenous immunoglobulin in the management of lupus nephritis. |
| Q26851698 | Intravenous immunoglobulin in the therapeutic armamentarium of systemic lupus erythematosus: a systematic review and meta-analysis |
| Q38495457 | Intravenous immunoglobulin in the treatment of neurologic disorders |
| Q33369794 | Intravenous immunoglobulin therapy and systemic lupus erythematosus |
| Q36359687 | Intravenous immunoglobulin therapy in vasculitis: speculation or evidence? |
| Q84506612 | Intravenous immunoglobulin-associated renal failure in a patient with post-transfusion purpura |
| Q37773248 | Intravenous immunoglobulin-based immunotherapy: an arsenal of possibilities for patients and science |
| Q36359670 | Intravenous immunoglobulin: adverse effects and safe administration |
| Q37578120 | Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside |
| Q83606479 | Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'? |
| Q50791354 | Long term safety of IVIg therapy in multiple sclerosis: 10 years experience |
| Q84510970 | Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases |
| Q37590659 | Neurological complications of chronic kidney disease |
| Q36227382 | Notes on the kidney and its diseases for the neurologist |
| Q37754557 | Novel approaches to therapy for systemic lupus erythematosus: update 2005. |
| Q98163647 | Patients with emm1/T1 serotype invasive group A streptococci infections demonstrated more renal failure than patients with other serotypes: perhaps we should consider some confounders |
| Q38542910 | Pharmacokinetic modeling of therapies for systemic lupus erythematosus. |
| Q88286738 | Pharmacology behind Common Drug Nephrotoxicities |
| Q33396342 | Renal impairment, hemoglobinuria, and hemoglobinemia among patients with idiopathic thrombocytopenic purpura |
| Q36319341 | Review: intravenous immunoglobulin therapy and thromboembolic complications |
| Q41221031 | Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease |
| Q37931231 | Special considerations with the use of intravenous immunoglobulin in older persons |
| Q39207717 | Sugar-free, glycine-stabilized intravenous immunoglobulin prevents skin but not renal disease in the MRL/lpr mouse model of systemic lupus |
| Q37754661 | The steroid-sparing effect of intravenous immunoglobulin in patients with autoimmune diseases |
| Q42728756 | Treatment of lupus nephritis |
| Q37508060 | Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. |
| Q37690745 | Update on emerging drug therapies for systemic lupus erythematosus |
| Q89289550 | [Acute kidney injury from intravenous immunoglobulins - an avoidable complication] |
Search more.